

**JAGADISHWAR PHARMACEUTICAL WORKS LIMITED**

(CIN : L24232AS1987PLC002803)

Regd Office : 205, HARIBOL ROY MARKET, 2nd FLOOR, A.T.ROAD, GUWAHATI - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email : jpw ltd@yahoo.com, Website : jagadishwarpharma.com, Tel : +91 9163513467

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020**


( In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.20	31.03.20	30.06.19	31.03.20
		Unaudited	Unaudited	Unaudited	Audited
<b>PART - I</b>					
I	Income From Operations	-	-	7.00	39.04
II	Other Income	-	5.62	-	9.61
III	Total Income from operations (I + II)	-	5.62	7.00	48.65
IV	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	15.41
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	0.00	5.41	20.86
	(d) Employee benefits expense	2.21	2.63	1.23	8.81
	(e) Depreciation and amortisation expense	-	-	-	-
	(f) Finance Cost	-	-	-	-
	(g) Other expenses	1.48	1.89	3.80	9.84
	Total Expenses	3.69	4.52	10.44	54.92
V	Profit (Loss) before exceptional Items and extraordinary items and tax (III-IV)	(3.69)	1.10	(3.44)	(6.27)
VI	Exceptional Items	-	-	-	-
VII	Profit from ordinary activities before finance costs and Exceptional Items (V-VI)	-	-	-	-
VIII	Extra Ordinary Items	-	-	-	-
IX	Net Profit/(Loss) before tax (VII-VIII)	(3.69)	1.10	(3.44)	(6.27)
X	Tax Expense :				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	-	-	-	-
	Total Tax Expenses	-	-	-	-
XI	<b>Net profit /(Loss) for the period from continuing operations (IX-X)</b>	(3.69)	1.10	(3.44)	(6.27)
XII	Profit /(Loss) for the period from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit /(Loss) for the period from discontinuing operations (after tax)	-	-	-	-
XV	<b>Profit (Loss) for the period (XI + XIV)</b>	(3.69)	1.10	(3.44)	(6.27)
XVI	Other Comprehensive Income	(44.29)	(44.29)	(44.29)	(44.29)
XVII	Total Comprehensive Income	(47.98)	(43.19)	(47.73)	(50.56)
XVIII	Paid up equity share capital (Face Value of Rs.10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02
XVIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	149.85
XX	Earnings Per Share (EPS)				
	(a) Basic	(0.01)	0.00	(0.01)	(0.02)
	(b) Diluted	(0.01)	0.00	(0.01)	(0.02)

**Notes :**

- The figures for the corresponding previous periods have been restated / regrouped, wherever necessary, to make them comparable.
- These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable .
- The Audit Committee reviewed the above results. The Board of Directors at its meeting held on 2nd September, 2020, approved the above results. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company does not have any reportable segment as per Indian Accounting Standard "Operating Segment" (Ind AS-108). Accordingly,

For Jagadishwar Pharmaceuticals Works Ltd.

  
**Mr. Swapan Sarkar**  
 Director

(DIN : 05149442)

Date : 02/09/2020

Place: Guwahati